vamorolone: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
vamorolone: clinical details
Prescribing considerations
- Initiation should be by a specialist experienced in managing Duchenne muscular dystrophy.
- Assess vaccination history, liver function, infection risk, thyroid disease, glaucoma risk, thromboembolic risk and interacting medicines.
- Provide an adrenal-crisis plan and Patient Alert Card; arrange additional corticosteroid cover for significant physiological stress where indicated.
- Do not reduce or stop treatment abruptly after ongoing use.
- This is an additional-monitoring medicine; report suspected adverse reactions through the Yellow Card Scheme.
Contraindications and cautions
- Hypersensitivity to vamorolone or an excipient
- Severe hepatic impairment
- Live or live-attenuated vaccination during treatment or within the preceding six weeks
Monitoring
- Clinical signs of adrenal suppression or crisis, particularly during illness, injury, surgery or treatment withdrawal
- Weight, appetite and behavioural effects
- Infection and regular blood-glucose assessment during chronic treatment
- Thyroid status and ocular effects where clinically relevant
- Potassium after starting a mineralocorticoid-receptor antagonist combination
- Hepatic status and the continuing need for treatment
Clinical pharmacology
Vamorolone is a dissociative corticosteroid that selectively activates glucocorticoid-receptor anti-inflammatory pathways and antagonises the mineralocorticoid receptor. It is extensively metabolised and has an approximate terminal half-life of two hours in children with Duchenne muscular dystrophy.
Formulation and product differences
- The selected product is a white to off-white oral suspension supplied with a bottle adapter and oral syringes.
- After first opening, keep the bottle upright in a refrigerator and discard any remainder after three months.
vamorolone preparations and strengths
Oral suspension
Route: Oral
Strengths: 40 mg/mL
vamorolone interactions
The specialist and pharmacist should review prescription, over-the-counter and herbal products before treatment.
Strong CYP3A4 inhibitors, including clarithromycin, telithromycin, itraconazole and voriconazole
These can increase vamorolone exposure; specialist review and treatment adjustment may be needed.
Grapefruit or grapefruit juice
May increase vamorolone exposure and should be avoided.
Strong CYP3A4 or PXR inducers, including carbamazepine, phenytoin, rifampicin and St John’s wort
These may lower vamorolone concentrations and reduce its effect; an alternative may be required.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.